Category Archives: Business of Biotech

Endocyte announces close of $26 million equity financing

Endocyte, Inc., completed a $26 million extension of its Series C financing. This round included participation from all existing institutional investors including Sanderling Ventures, Burrill & Company, American Bailey Ventures, Blue Chip Venture Company, and Triathlon Medical Ventures. Clarian Health Ventures also participated as a new investor.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Targacept reports positive Phase 2b trial results for depression treatment

Targacept, Inc. (NASDAQ: TRGT) presented data from its Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.  In the trial, the add-on TC-5214 arm (TC-5214 + citalopram) outperformed the add-on placebo arm (placebo + citalopram) on the primary outcome measure, the Hamilton Rating Scale for Depression-17, or HAM-D, and all of the secondary Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Q&A with ExonHit Therapeutics’ Loïc Maurel, MD

We recently spoke with Loïc Maurel, M.D., president of ExonHit Therapeutics’ Management Board, one of the companies presenting at the Eighth Annual BIO Investor Forum: Can you describe the top priorities or upcoming milestones for your company? This year will be the first year of product commercialization for ExonHit with the launch of EHT Dx21, a blood-based diagnostic test for Alzheimer’s disease. The Company is also focused on the outlicensing of EHT 0202, ExonHit’s lead Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Inovio begins HIV clinical trial of DNA vaccine

Inovio Biomedical Corporation (NYSE Amex: INO) and the HIV Vaccine Trials Network (HVTN) initiated a phase I clinical study of Inovio’s PENNVAX™-B preventive DNA vaccine delivered using electroporation technology. The multi-center study will be conducted at several HVTN clinical sites under a protocol designated HVTN-080. The study will enroll healthy volunteers to assess the safety of and immune responses to this DNA-based vaccine delivered via in vivo electroporation. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Methylgene to receive equity investment from Otsuka Pharmaceutical

MethylGene Inc. (TSX: MYG) agreed to issue 3,686,182 common shares to Otsuka Pharmaceutical Co., Ltd. as part of a research collaboration and license agreement for the development of  small molecule kinase inhibitors for ocular diseases excluding cancer. Otsuka will acquire newly issued common shares of MethylGene at a purchase price of approximately $0.43 per share for gross proceeds of $1,500,000. In September 2009, MethylGene announced that Otsuka had extended the research portion of the collaboration Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,